Publications by authors named "Maria Jazmin Toloza"
Article Synopsis
- The immune system in chronic myeloid leukemia (CML) patients is significantly weakened, affecting their ability to respond to tumors, but shows improvement following effective treatment with tyrosine kinase inhibitors like imatinib.
- A study analyzed gene expression of various immune mediators in 171 blood samples from CML patients over their first year on imatinib, comparing it with samples from healthy donors.
- Results indicated that most immune mediators initially declined but largely normalized over time, while also revealing different patterns in optimal versus non-optimal treatment responders.
The use of tyrosine kinase inhibitors seems to restore the broadly compromised immune system described in chronic myeloid leukaemia (CML) patients at diagnosis leading to a re-activation of the effector-mediated immune surveillance. Here, we describe the expression dynamics of immune factors during the first year on imatinib therapy. Gene expression was evaluated in 132 peripheral blood samples from 79 CML patients, including 34 who were serially followed.
View Article and Find Full Text PDF